Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald G Long

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Toxicologic Pathology|October 10, 2002
Apparent mesonephric duct (rete anlage) origin for cysts and proliferative epithelial lesions in the mouse ovaryGerald G Long
Toxicologic Pathology|May 16, 2012
Regulatory forum opinion piece: thresholds in toxicologic pathologyGerald G Long, Jerry F Hardisty
Toxicologic Pathology|November 17, 2009
Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretationGerald G Long, Daniel Morton, Terry Peters, et al.
Toxicologic Pathology|August 25, 2009
Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonistGerald G Long, Vincent L Reynolds, L Wayne Dochterman, et al.
Toxicologic Pathology|June 19, 2004
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and doseJohn L Vahle, Gerald G Long, George Sandusky, et al.
Toxicologic Pathology|October 2, 2010
Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNUGerald G Long, Dawn G Goodman, Kelly M Credille, et al.
Toxicologic Pathology|May 14, 2008
Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting eventGerald G Long, Vincent L Reynolds, Alric Lopez-Martinez, et al.
Toxicologic Pathology|November 4, 2009
Panel discussion: alternative mouse models for carcinogenicity assessmentJohn E French, Bernard Leblanc, Gerald G Long, et al.
Regulatory Toxicology and Pharmacology : RTP|April 9, 2017
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)Jacquelin Jolette, Bassem Attalla, Aurore Varela, et al.
Toxicologic Pathology|June 8, 2002
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safetyJohn L Vahle, Masahiko Sato, Gerald G Long, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Toxicologic Pathology|October 10, 2002
Apparent mesonephric duct (rete anlage) origin for cysts and proliferative epithelial lesions in the mouse ovaryGerald G Long
Toxicologic Pathology|May 16, 2012
Regulatory forum opinion piece: thresholds in toxicologic pathologyGerald G Long, Jerry F Hardisty
Toxicologic Pathology|November 17, 2009
Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretationGerald G Long, Daniel Morton, Terry Peters, et al.
Toxicologic Pathology|August 25, 2009
Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonistGerald G Long, Vincent L Reynolds, L Wayne Dochterman, et al.
Toxicologic Pathology|June 19, 2004
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and doseJohn L Vahle, Gerald G Long, George Sandusky, et al.
Toxicologic Pathology|October 2, 2010
Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNUGerald G Long, Dawn G Goodman, Kelly M Credille, et al.
Toxicologic Pathology|May 14, 2008
Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting eventGerald G Long, Vincent L Reynolds, Alric Lopez-Martinez, et al.
Toxicologic Pathology|November 4, 2009
Panel discussion: alternative mouse models for carcinogenicity assessmentJohn E French, Bernard Leblanc, Gerald G Long, et al.
Regulatory Toxicology and Pharmacology : RTP|April 9, 2017
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)Jacquelin Jolette, Bassem Attalla, Aurore Varela, et al.
Toxicologic Pathology|June 8, 2002
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safetyJohn L Vahle, Masahiko Sato, Gerald G Long, et al.
Pageof 2